Literature DB >> 20672353

Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group.

Leo Kager1, Andreas Zoubek, Martin Dominkus, Susanna Lang, Nicole Bodmer, Gernot Jundt, Thomas Klingebiel, Heribert Jürgens, Helmut Gadner, Stefan Bielack.   

Abstract

BACKGROUND: This study was conducted to investigate presentation, treatment, and outcome in very young children with osteosarcoma.
METHODS: The authors retrospectively analyzed the data of 2706 consecutive COSS patients with newly diagnosed osteosarcoma and identified 28 (1.0%) patients aged younger than 5 years at diagnosis. Demographic, diagnostic, tumor, treatment-related variables, response, and survival data were analyzed.
RESULTS: Of the 28 preschoolers, 27 presented with high-grade central osteosarcoma of an extremity, and 1 had a secondary osteosarcoma of the orbit. This analysis focused on the 27 patients with extremity tumors. The size of the primary was large (≥one-third of the involved bone) in 20 of 27 patients. Primary metastases were detected in 4 of 27 children. All patients received multiagent chemotherapy, and 11 of 18 analyzed tumors responded well (>90% necrosis) to neoadjuvant chemotherapy. Limb-sparing surgery was performed in 9 cases, ablative procedures were performed in 15, and, in 3 cases, no local surgery was performed. With a median follow-up of 4 years (6.2 years for survivors), 13 patients were alive. Four patients never achieved a complete remission, and 11 developed recurrences; 14 of these 15 patients died. Five-year overall and event-free survival probabilities were 51% (standard error of the mean [SE], 10%) and 48% (SE, 10%). Better survival was correlated with good response to chemotherapy and later time period of diagnosis.
CONCLUSIONS: Osteosarcoma is extremely rare in preschool children. These patients often have large tumors that may require mutilating resections. Prognosis is in the range of that reported for older patients.
Copyright © 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 20672353     DOI: 10.1002/cncr.25287

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Osteoporosis in children and young adults: a late effect after chemotherapy for bone sarcoma.

Authors:  Ulrike Michaela Pirker-Frühauf; Jörg Friesenbichler; Ernst-Christian Urban; Barbara Obermayer-Pietsch; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2012-07-18       Impact factor: 4.176

2.  MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88.

Authors:  Fan Zhang; Yanjie Zhu; Guoxin Fan; Shuo Hu
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

3.  In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.

Authors:  Ye-Teng He; Qing-Min Zhang; Quan-Chun Kou; Bo Tang
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

4.  Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.

Authors:  Masanori Kawano; Ichiro Itonaga; Tatsuya Iwasaki; Hiroyuki Tsuchiya; Hiroshi Tsumura
Journal:  Clin Orthop Relat Res       Date:  2012-03-14       Impact factor: 4.176

5.  Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.

Authors:  Maud A M Guillon; Pierre M J Mary; Laurence Brugière; Perrine Marec-Bérard; Hélène D Pacquement; Claudine Schmitt; Jean-Marc Guinebretière; Marie-Dominique P Tabone
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

6.  The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.

Authors:  Xiaodong Mu; Daniel Brynien; Kurt R Weiss
Journal:  Biomed Res Int       Date:  2015-02-17       Impact factor: 3.411

Review 7.  Pediatric Osteosarcoma: An Updated Review.

Authors:  Shachi Jain Taran; Rakesh Taran; Nagraj B Malipatil
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jan-Mar

Review 8.  Anti-cancer properties of quercetin in osteosarcoma.

Authors:  Parisa Maleki Dana; Fatemeh Sadoughi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2021-07-05       Impact factor: 5.722

9.  Serum tumor markers in pediatric osteosarcoma: a summary review.

Authors:  Yulia A Savitskaya; Genaro Rico-Martínez; Luis Miguel Linares-González; Ernesto Andrés Delgado-Cedillo; René Téllez-Gastelum; Alfonso Benito Alfaro-Rodríguez; Antonio Redón-Tavera; José Clemente Ibarra-Ponce de León
Journal:  Clin Sarcoma Res       Date:  2012-03-23

Review 10.  UK guidelines for the management of bone sarcomas.

Authors:  Craig Gerrand; Nick Athanasou; Bernadette Brennan; Robert Grimer; Ian Judson; Bruce Morland; David Peake; Beatrice Seddon; Jeremy Whelan
Journal:  Clin Sarcoma Res       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.